Response: Commentary: An In Silico–In Vitro Pipeline Identifying an HLA-A*02:01+ KRAS G12V+ Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients

• Michele Mishto,
• Michele Mishto,
• Guillermo Rodriguez-Hernandez,
• Guillermo Rodriguez-Hernandez,
• Jacques Neefjes,
• Henning Urlaub,
• Henning Urlaub,
• Juliane Liepe

Affiliations

Michele Mishto

Centre for Inflammation Biology and Cancer Immunology (CIBCI) & Peter Gorer Department of Immunobiology, King’s College London, London, United Kingdom

Michele Mishto

Francis Crick Institute, London, United Kingdom

Guillermo Rodriguez-Hernandez

Centre for Inflammation Biology and Cancer Immunology (CIBCI) & Peter Gorer Department of Immunobiology, King’s College London, London, United Kingdom

Guillermo Rodriguez-Hernandez

Francis Crick Institute, London, United Kingdom

Jacques Neefjes

Department of Cell and Chemical Biology, Oncode Institute, Leiden University Medical Center (LUMC), Leiden, Netherlands

Henning Urlaub

Max-Planck-Institute for Biophysical Chemistry, Göttingen, Germany

Henning Urlaub

Bioanalytics, Institute of Clinical Chemistry, University Medical Center, Göttingen, Germany

Juliane Liepe

Max-Planck-Institute for Biophysical Chemistry, Göttingen, Germany